Besins Healthcare to produce infertility drugs in Russia

21 April 2017

Bangkok, Thailand-based Besins Healthcare has announced plans to build a new plant for the production of drugs to treat infertility in the Yaroslavl region of Russia, according to recent statements of an official spokesman of the Yaroslavl regional government, reports The Pharma Letter’s local correspondent.

The new plant will be built in the local industrial park, known as Novoselki. Construction is scheduled to begin in 2017, with production to commence in 2019. The new plant will produce Utrogestan, a micronized progesterone in capsule formwhich is included in the all-Russian list of vital drugs on the basis of full cycle.

The value of the investment in the project at the initial stage will amount to $30 million with the possibility of this to increase during the next stages of the project.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK